Todd James
Keine laufenden Positionen mehr
Karriereverlauf von Todd James
Ehemalige bekannte Positionen von Todd James
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Investor Relations Kontakt | 01.01.2022 | 01.10.2023 |
| Corporate Officer/Principal | 01.01.2022 | 01.10.2023 | |
| ACCELERON PHARMA INC. | Investor Relations Kontakt | 01.01.2015 | 01.12.2021 |
| Public Communications Contact | 01.01.2015 | 01.12.2021 | |
Trout Capital LLC
 Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Marktstratege | 01.09.2006 | 01.08.2015 |
Ausbildung von Todd James
| Moravian College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Investor Relations Contact | 2 |
| Market Strategist | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Trout Capital LLC
Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Finance |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Todd James
- Erfahrung
